HFS
DNLI icon

Hantz Financial Services’s Denali Therapeutics DNLI Stock Holding History

Hantz Financial Services’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Hold
57
– – ﹤0.01% 2345
2025
Q4 		$1K Buy
+57
New +$962 ﹤0.01% 2315

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hantz Financial Services's DNLI Position: Q1 2026 in Review

Hantz Financial Services held its Denali Therapeutics (DNLI) position steady in Q1 2026 at 57 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2345.

Hantz Financial Services first reported a position in DNLI in Q4 2025 and has held it in 2 quarters since. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Hantz Financial Services held 57 shares of Denali Therapeutics worth $1K as of Q1 2026.
  • Hantz Financial Services left its Denali Therapeutics share count unchanged in Q1 2026.
  • Denali Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #2345 holding.
  • Hantz Financial Services first reported a position in Denali Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.